Monte Rosa Q2 net loss $30.3M; cash $267.1M; IND cleared for MRT-6160

Monte Rosa Therapeutics, Inc.

Net loss $30.3M for Q2 2024 vs $32.0M in Q1; collaboration revenue $4.7M from Roche deal.
Cash, equivalents, securities $267.1M at June 30, 2024; expected to fund operations into H1 2027.
IND accepted by FDA for VAV1-directed MGD MRT-6160; Phase 1 SAD/MAD to start summer with data expected Q1 2025.
MRT-2359 Phase 1/2 dose escalation ongoing at 0.75 mg 21/7 schedule; RP2D determination and updated results expected H2 2024.
Achieved first research milestones and payments from Roche collaboration; $100M public offering completed in May.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.